Cozaar Side Effects

Cozaar has been found to be generally well tolerated. Side effects have usually been mild and transient in nature and have not required discontinuation of therapy. The overall incidence of side effects reported with Cozaar was comparable to placebo.
In controlled clinical trials for essential hypertension, dizziness was the only side effect reported as drug related that occurred with an incidence greater than placebo in ≥1% of patients treated with Cozaar. In addition, dose-related orthostatic effects were seen in <1% of patients. Rarely, rash was reported, although the incidence in controlled clinical trials was less than placebo.
Laboratory Test Findings: In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of Cozaar. Hyperkalemia (serum potassium >5.5 mEq/L) occurred in 1.5% of patients, but in these trials, discontinuation of losartan therapy due to hyperkalemia was not necessary. Elevations of ALT occurred rarely and usually resolved upon discontinuation of therapy.
Serum potassium should be monitored particularly in the elderly and patients with renal impairment.